Effect of Pleuran on the Clinical Course of Patients With Chronic Rhinosinusitis

Inclusion Criteria: * age over 12 years * signed informed consent * patients with newly diagnosed CRS without nasal polyps (meeting the criteria for the definition of CRS according to EPOS) * patients without anatomical abnormalities causing nasal obstruction (nasal septal deformity, nasal turbinate hyperplasia, tumours, craniofacial deformities) * patients able and willing to complete the questionnaires, undergo rhinoendoscopic examination, upper aerodigestive tract swabs and follow-up outpatient examinations Exclusion Criteria: * refused informed consent * inability/unwillingness to complete the questionnaire, undergo rhinoendoscopic examination, upper aerodigestive tract swabs, follow-up outpatient examinations * inability/unwillingness to use the product in accordance with the research protocol and compliance \< 75% * patients with protracted rhinosinusitis, exacerbations rhinosinusitis with the presence of an asymptomatic period * patients with CRS during conservative treatment * patients with CRS after previous surgical treatment * patients with grade 3 nasal polyps * patients with adenoid vegetations/persistent pharyngeal tonsils (especially if children are included in the study) * patients with CRS with anatomical abnormalities causing nasal obstruction (septal deformity, turbinate hyperplasia, tumors, craniofacial abnormalities) * patients with significant immunodeficiency * patients with mucociliary transport disorders (e.g. cystic fibrosis, primary ciliary dyski…